Statement from Novo Nordisk on Rebinyn and COVID-19

Written by Jennifer DeGlopper

Novo Nordisk released this advisory to physicians, hematologists, and other healthcare professionals that the factor IX product Rebinyn may interfere with some laboratory tests being used to measure blood coagulation in COVID-19 patients.

Read press release
novo_logo.png
 
Jennifer DeGlopper https://www.jenniferlynne.net
Previous

"The Fight Is in Us": Effort to Find COVID-19 Plasma Donors
Next

Update from Dr. David Clark: Hemophilia and COVID-19